TP53 and neoplasm: We have previously demonstrate that co-delivery of Cas9 with an sgRNA targeting p53 (pQCiG/sgp53-3) in Eμ-Myc HSPCs ex vivo accelerated tumor onset rates in transplanted normal, syngeneic recipients (Malinaet al. 2013).